CD8A and neoplasm: Additionally, the administration of apatinib at low doses can alleviate hypoxia, increase the infiltration of CD8+ T cells, reduce the recruitment of tumor-associated macrophages, and lower the level of transforming growth factor-β in both tumor and serum, thereby changing the tumor microenvironment (TME) and enhancing the activity of anticancer drugs (19).